A Phase 1 safety and feasibility of AGT-103

Trial Profile

A Phase 1 safety and feasibility of AGT-103

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs AGT-103 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Oct 2017 According to an American Gene Technologies International media release, the company expects to file its IND with the Food and Drug Administration during the first quarter of 2018 and interim safety and early efficacy data are expected by the third quarter of 2018.
    • 12 Apr 2017 According to an American Gene Technologies International media release, company intends to initiate this trial later in 2017.
    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top